The partnership between Rain Cage Carbon and Voyageur Pharmaceuticals (TSXV:VM), a company focused on developing barium, iodine and carbon-active pharmaceutical imaging drugs, is transforming carbon capture and reuse technology, and investors are taking notice.
Rain Cage Carbon, which is a company dedicated to transforming CO2 emissions into high-value advanced and engineered carbons, recently announced a co-marketing and master purchase agreement with Toyota Tsusho Canada.
Rain Cage Carbon is disrupting the graphite market
Toyota Tsusho Canada is a multi-market enterprise focused on vehicle manufacturers and parts suppliers.
It is anticipated the collaboration will leverage Rain Cage Carbon’s global carbon farm decarbonization initiatives, including its advanced carbon, into Toyota Group’s supply chains.
“Working with Grant (Town, Toyota Tsuho Canada president) and Toyota Tsusho Canada over the past 18 months has fostered a collaboration to harness our common aspirations for both global societal benefits and cutting-edge business innovation,” Blair Aiken, CEO of Rain Cage Carbon, said in a statement.
Through the agreement, Rain Cage Carbon will leverage its proprietary EDENTM Carbon Capture and Reuse System to supply Toyota Tsusho Canada with Advanced Carbon products. It is expected these materials will be crucial in manufacturing current and next-generation electric vehicles, plug-in hybrids, and hydrogen vehicles that will effectively disrupt the graphite market.
What this means for Voyageur Pharmaceuticals
The partnership between Rain Cage Carbon and Voyageur Pharmaceuticals began in May 2023 when Voyageur Pharmaceuticals announced its licensing agreement with Rain Cage.
The collaboration stems from Voyageur Pharmaceuticals’ belief that Rain Cage has achieved a significant technological breakthrough with the pioneering EDEN system, a technology capable of directly capturing CO2 and various other oxides from industrial emissions.
“Our vision is to become the world’s first company capable of creating new carbon-based drugs from captured CO2, ensuring carbon-neutral pharmaceuticals,” Voyageur Pharmaceuticals CEO Brent Willis said in a previous statement.
Rain Cage doing a deal with Toyota does lend credibility to Voyageur’s strategy when it comes to using carbon capture to create a new pipeline for contrast imaging drugs.
Voyageur Pharmaceuticals and Rain Cage Carbon follow-up
On June 11, Voyageur Pharmaceuticals announced it and Rain Cage Carbon are following up on the first commercial creation of a V@C60endohedral fullerene, which is Vanadium atom inside a C60 molecule.
It was revealed in a press release that Rain Cage is undertaking the next phase of radiology drug development by utilizing its cutting-edge technology. Rain Cage will begin testing to create on a commercial scale, the encapsulation of gadolinium, bismuth and iodine within endohedral fullerenes.
The objective will be to develop a process to create Gd@C60, Bi@C60 and I@C60 endohedral fullerenes, targeting the development of highly advanced radiology contrast agents for Magnetic Resonance Imaging (MRI) and CT scans.
“We are thrilled to be at the forefront of this groundbreaking initiative that marries cutting-edge nanotechnology with pharmaceutical innovation. Our collaboration with Rain Cage in my view marks a pivotal moment in medical science, where the development of endohedral fullerenes promises not just advancements in radiology, but a paradigm shift in how we approach diagnostic imaging. I believe this is just the beginning of a transformative journey towards revolutionizing healthcare solutions for the benefit of patients worldwide,” Willis said in a statement.
The investment corner
Rain Cage’s technology marks a real shift using carbon capture to provide advanced carbon products and is set to be a game-changer in many different aspects of our everyday life – from health and life sciences to electric vehicles – and Voyageur Pharmaceuticals, which deserves kudos for seeing this potential, is at the forefront of this innovation.
This is yet another intriguing aspect of Voyageur’s business, following on from its recent announcement of its first international sales agreement in Latin America last month.
As the company marches towards product development, manufacturing and commercialization, investors will be keenly watching to see how it will transform the industry and beyond.
Join the discussion: Find out what everybody’s saying about this stock on the Voyageur Pharmaceuticals Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
This is sponsored content issued on behalf of Voyageur Pharmaceuticals, please see the full disclaimer here.
